Testin

Testin also known as TESS is a is_associated_with::protein that in humans is encoded by the TES is_associated_with::gene located on is_associated_with::chromosome 7. TES is a 47 is_associated_with::kDa protein composed of 421 is_associated_with::amino acids found at is_associated_with::focal adhesions and is thought to have a role in regulation of is_associated_with::cell motility. In addition to this, TES functions as a is_associated_with::tumour suppressor. The TES gene is located within a fragile region of is_associated_with::chromosome 7, and the promoter elements of the TES gene have been shown to be susceptible to is_associated_with::methylation - this prevents the expression of the TES protein. TES came to greater prominence towards the end of 2007 as a potential mechanism for its tumour suppressor function was published.

Domain organisation
Tes is composed of the following domains:

The structures of the Cysteine rich domain and the PET domain are not known. LIM domains, however, are known as modulators of protein interactions. LIM domain consist of 2 is_associated_with::zinc fingers separated by 2 hydrophobic amino acids (generally a is_associated_with::phenylalanine and then a is_associated_with::leucine).

Binding partners
TES does not appear to be an is_associated_with::enzyme; rather it is a protein that mediates/regulates cellular functions via Protein:protein interactions. Pull down experiments reveal that TES has putative interactions mediated by the indicated domain:

Garvalov et al. showed that the interaction between TES & zyxin were direct, using recombinant proteins expressed in E. coli.

Some of the potential binding partners (Zyxin, mENA) can be found in is_associated_with::focal adhesion complexes; the range of binding partners indicates a potential role for TES in-between 'privileged' is_associated_with::Actin polymerisation and focal adhesion contacts to the is_associated_with::extracellular matrix. This tallies with the observation that GFP-tagged TES can be seen at focal adhesions.

TES as a tumour suppressor
In December 2007, Boeda, Briggs et al. showed that the third LIM domain of TES displaces Mena from its usual subcellular positions (is_associated_with::focal adhesions or the cell leading edge). The ENA/VASP protein family (of which Mena is a member) are anchored to specific proteins within the cell by a is_associated_with::peptide motif consisting of a is_associated_with::phenylalanine residue, followed by four is_associated_with::proline residues - known as a FPPPP motif. It is the is_associated_with::EVH1 domains of VASP/EVL proteins that directly contact the FPPPP motif. The precise architecture of TES:MENA binding was revealed by is_associated_with::X-ray crystallography, and showed that the 3rd LIM domain of TES covered up the FPPPP binding site within Menas EVH1 domain. is_associated_with::Isothermal titration calorimetry showed that TES has a greater affinity for Mena than its canonical FPPPP ligand, as presented in the focal adhesion protein zyxin. Using microscopy it was shown that either over-expression of GFP-tagged TES, or just the tagged third LIM domain displaced Mena from focal adhesions and reduced mean cell velocity.

These finding were significant given that Mena is often over-expressed in is_associated_with::cancer cells, and is thought to be partly responsible for cancer cell motility, and therefore a factor in cancer is_associated_with::metastasis. TES is conversely often not produced in cancer cells. It is possible that a drug designed to mimic TES's interaction with Mena could be used to prevent metastasis and thus development of secondary tumours in cancer patients. The work was widely reported in the British press (the work was carried out by is_associated_with::Cancer Research UK),  and also in the international press.

Conformational Change
Based on the observations that: Garvalov et al. propose that TES exists in two conformational states: A 'closed' state where the N & C halves of TES interact, obscuring the Zyxin binding site in LIM1, and an 'open' state where the Zyxin binding site is accessible and the two halves no-longer interact in the same fashion, if at all. The regulatory mechanism switching between the two states is not presently fully understood.
 * Mammalian cell derived TES binding Zyxin
 * E. coli produced recombinant TES (rTES) does not bind Zyxin
 * An rTES construct composed of residues 201-421 (i.e., the linker and all 3 LIM domains) does bind Zyxin
 * The above rTES construct binds an N-terminal rTES construct, consisting of the cysteine rich and PET domains - IE, the two halves of TES interact with each other.

Phenotype
In is_associated_with::RNAi experiments, cells that had impaired TES expression showed an inability to correctly organise their is_associated_with::focal adhesions and is_associated_with::actin stress fibres.

In gene knockout experiments, is_associated_with::transgenic mice lacking both copies of the TES gene displayed an increased susceptibility to is_associated_with::tumour formation when challenged with a carcinogen. Mice retaining the TES gene were less susceptible: thus, TES is a tumour suppressor gene.